These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 24703530)
1. Exploring better strategies for EGFR antibodies in colon cancer. Cervantes A Lancet Oncol; 2014 May; 15(6):549-50. PubMed ID: 24703530 [No Abstract] [Full Text] [Related]
2. How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? Lindsay CR; Roxburgh P; Graham J Future Oncol; 2013 Jun; 9(6):825-9. PubMed ID: 23718303 [TBL] [Abstract][Full Text] [Related]
11. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090 [TBL] [Abstract][Full Text] [Related]
12. Cetuximab in colon cancer. Giuliani F; Colucci G Int J Biol Markers; 2007; 22(1 Suppl 4):S62-70. PubMed ID: 17520583 [TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. László L Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770 [TBL] [Abstract][Full Text] [Related]
14. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Negri FV; Musolino A; Naldi N; Bortesi B; Missale G; Laccabue D; Zerbini A; Camisa R; Chernyschova N; Bisagni G; Loupakis F; Ruzzo A; Neri TM; Ardizzoni A Pharmacogenomics J; 2014 Feb; 14(1):14-9. PubMed ID: 23296156 [TBL] [Abstract][Full Text] [Related]
16. [First/second/third-line chemotherapy with molecular targeted drugs for colorectal cancer]. Sato A; Nakamachi M; Imataka H Gan To Kagaku Ryoho; 2009 Aug; 36(8):1242-6. PubMed ID: 19692761 [TBL] [Abstract][Full Text] [Related]